权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting Senescence to Mitigate Chemotherapy-induced Functional Decline

靶向衰老以减轻化疗引起的功能衰退

基本信息

批准号：
10638071
负责人：
Mina S Sedrak
金额：
$ 70.06万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-01 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10638071
关键词：
Ablation Acceleration Address Adherence Age Aging Biological Aging Biological Markers Breast Cancer Treatment Breast Cancer survivor CD3 Antigens CDKN2A gene Cancer Patient Cell Aging Cell Cycle Arrest Cells Cessation of life Chemotherapy-Oncologic Procedure Chronic Disease Clinical Clinical Markers Data Diabetes Mellitus Elderly Exercise Fatigue Functional disorder Geriatric Assessment Growth Health Inflammation Inflammatory Intervention Link Malignant Neoplasms Measures Neuropathy Oncology Oral Patients Pharmaceutical Preparations Phase Phenotype Physical Function Population Postmenopause Process Public Health Pulmonary Fibrosis Quality of life Randomized Risk Survivors T-Lymphocyte Testing Tissues Toxicity due to chemotherapy Treatment-related toxicity United States National Institutes of Health Walking Woman Work age related arm cancer therapy chemotherapy clinical practice comparative efficacy design dietary supplements disability efficacy evaluation efficacy testing exercise program exercise training experience falls fisetin frailty functional decline improved malignant breast neoplasm middle age muscle form older patient preclinical study premature prevent primary endpoint randomized placebo controlled trial restoration safety assessment secondary endpoint senescence tele-exercise therapy design treatment arm young adult

项目摘要

PROJECT SUMMARY/ABSTRACT Advances in breast cancer treatment have resulted in significant survival gains. However, cure or control of breast cancer is not necessarily accompanied by full restoration of health. We have shown that as breast cancer survivors age, they experience accelerated chemotherapy-induced functional decline compared to age-matched survivors not treated with chemotherapy and women without cancer. Chemotherapy-induced functional decline results in poor quality of life, loss of independence, and premature death. The proposed study builds on our clinical work showing that cellular senescence is a central process linked to chemotherapy-induced functional decline. Cellular senescence is a fundamental aging process characterized by cell cycle arrest. Senescent cells accumulate in aging tissues and secrete proinflammatory factors that drive age-related functional decline. We have observed that, in breast cancer survivors, chemotherapy induces the persistent presence of high levels of circulating senescent cells, and that survivors with high senescent cell burden are more likely to experience chemotherapy-induced fatigue, neuropathy, and functional decline. These data provide rationale for targeting and reducing senescent cells to alleviate chemotherapy-induced functional decline. In non-cancer populations, senescent cells can be reduced through use of exercise or senolytics (drugs that ablate senescent cells). Recent preclinical studies also showed that senolytics combined with exercise yielded a greater reduction in senescent cells compared to either intervention alone. However, the ability of exercise and senolytics to reduce senescent cells and, ultimately, improve physical function in breast cancer survivors has not been tested. We hypothesize that targeting senescent cells via exercise and senolytics in breast cancer survivors will yield independent and additive effects to improve physical function and reduce markers of biological aging. To test this hypothesis, we propose a multicenter randomized placebo-controlled trial to test the efficacy of exercise and senolytic therapy (alone or combined) on physical function and markers of biological aging. We will randomize chemotherapy- treated postmenopausal breast cancer survivors with diminished function, assessed using the 6-minute walk distance [6MWD], to 1 of 4 arms: exercise + senolytic; exercise alone; senolytic alone; or control. The primary endpoint will be the change in 6MWD from baseline to end of treatment (Aim 1). Secondary endpoints include clinical and biological aging markers (Aim 2). We also will assess the safety and adherence of both interventions. In summary, as the number of breast cancer survivors rises dramatically (estimated to be >6 million by 2040), mitigating chemotherapy-induced functional decline is an urgent public health issue and a priority of the NIH. Successful completion of this trial will establish the efficacy of two targeted treatments to mitigate chemotherapy- induced functional decline. Given that senescence underlies many mid- and late-life chronic diseases, a safe treatment that improves physical function would have a major positive impact that extends far beyond oncology.